Orris

pyoderma gangrenosum management

Reading File
Finding Sources
Finding Sources
Searching PubMed

"pyoderma gangrenosum"[MeSH Terms] AND treatment

Searching Images

pyoderma gangrenosum ulcer clinical appearance

Clinical photograph series showing cutaneous manifestations of pyoderma gangrenosum. Image A displays the lower limbs with multiple erythematous nodules and deep ulcers. These lesions feature well-defined, slightly raised, violet-brownish borders and a characteristic cribriform (sieve-like) appearance in the ulcer bed, accompanied by perilesional erythema. Image B focuses on the dorsal trunk, presenting a violet papule with central vesiculation and two smaller satellite papules. Image C shows a similar ulcerated plaque on the volar aspect of the wrist/hand. The morphology is consistent with neutrophilic dermatosis often associated with systemic conditions or vasculitis. Educational focus includes the recognition of undermined borders and cribriform scarring typical of pyoderma gangrenosum. These clinical findings are relevant for dermatology and internal medicine, particularly in the context of identifying diagnostic cutaneous markers for underlying systemic inflammatory or toxicological causes.

Clinical photograph series showing cutaneous manifestations of pyoderma gangrenosum. Image A displays the lower limbs with multiple erythematous nodules and deep ulcers. These lesions feature well-defined, slightly raised, violet-brownish borders and a characteristic cribriform (sieve-like) appearance in the ulcer bed, accompanied by perilesional erythema. Image B focuses on the dorsal trunk, presenting a violet papule with central vesiculation and two smaller satellite papules. Image C shows a similar ulcerated plaque on the volar aspect of the wrist/hand. The morphology is consistent with neutrophilic dermatosis often associated with systemic conditions or vasculitis. Educational focus includes the recognition of undermined borders and cribriform scarring typical of pyoderma gangrenosum. These clinical findings are relevant for dermatology and internal medicine, particularly in the context of identifying diagnostic cutaneous markers for underlying systemic inflammatory or toxicological causes.

This clinical photograph displays a large, complex skin ulcer characteristic of Pyoderma Gangrenosum. The lesion features a deep central cavity with an irregular, necrotic base containing dark, devitalized tissue. The borders of the ulcer are poorly defined and notably undermined, with a violaceous or dusky hue. Surrounding the primary ulceration is a broad zone of intense erythema and inflammatory induration. The periphery of the lesion shows evidence of crusting, scaling, and small pustular elements, suggesting active progression. The overall appearance is consistent with an aggressive, inflammatory neutrophilic dermatosis, emphasizing the classic 'undermined' edge and necrotic floor used for clinical diagnosis in dermatology.

This clinical photograph displays a large, complex skin ulcer characteristic of Pyoderma Gangrenosum. The lesion features a deep central cavity with an irregular, necrotic base containing dark, devitalized tissue. The borders of the ulcer are poorly defined and notably undermined, with a violaceous or dusky hue. Surrounding the primary ulceration is a broad zone of intense erythema and inflammatory induration. The periphery of the lesion shows evidence of crusting, scaling, and small pustular elements, suggesting active progression. The overall appearance is consistent with an aggressive, inflammatory neutrophilic dermatosis, emphasizing the classic 'undermined' edge and necrotic floor used for clinical diagnosis in dermatology.

Two-panel clinical photograph demonstrating bullous pyoderma gangrenosum. Image A displays the posterior trunk (back) with multiple shallow ulcers characterized by a bright red, beefy granulating base and irregular, slightly elevated borders. The surrounding skin shows perilesional erythema and inflammation. Image B shows the upper limb with similar ulcerative lesions. A key diagnostic feature visible is the distinctive blue-gray or violaceous hue at the ulcer margins. The lesions vary in appearance from active erosions with red bases to ones with dark, hemorrhagic crusting or scabbing. This presentation illustrates a neutrophilic dermatosis often associated with underlying systemic conditions such as hematologic malignancies or inflammatory bowel disease. The educational focus is on identifying the characteristic undermined, dusky borders and the progression from bullae to shallow ulcers typical of the bullous variant of pyoderma gangrenosum.

Two-panel clinical photograph demonstrating bullous pyoderma gangrenosum. Image A displays the posterior trunk (back) with multiple shallow ulcers characterized by a bright red, beefy granulating base and irregular, slightly elevated borders. The surrounding skin shows perilesional erythema and inflammation. Image B shows the upper limb with similar ulcerative lesions. A key diagnostic feature visible is the distinctive blue-gray or violaceous hue at the ulcer margins. The lesions vary in appearance from active erosions with red bases to ones with dark, hemorrhagic crusting or scabbing. This presentation illustrates a neutrophilic dermatosis often associated with underlying systemic conditions such as hematologic malignancies or inflammatory bowel disease. The educational focus is on identifying the characteristic undermined, dusky borders and the progression from bullae to shallow ulcers typical of the bullous variant of pyoderma gangrenosum.

Reading File
Reading File
Reading File
Reading File
Reading Article

PMID: 40740034

Reading Article

PMID: 39158753

Reading File
I now have comprehensive information to write a thorough answer. Let me compile it.

Pyoderma Gangrenosum (PG): Management

Pyoderma gangrenosum - deep ulcer with undermined violaceous borders

Overview

Pyoderma gangrenosum is a rare, painful neutrophilic dermatosis characterized by rapidly enlarging ulcers with undermined, purple-to-gray borders. About 50% of cases are associated with an underlying condition (IBD, rheumatoid arthritis, hematologic disorders). Management is challenging - there are no consensus guidelines, and the 2025 meta-analysis (PMID: 40740034) found a pooled complete healing rate of only 59% across systemic therapies, with a 30% recurrence rate.
The two pillars of management are: (1) treating the underlying disease and (2) suppressing skin inflammation while promoting wound healing.

Diagnostic Caveat Before Treatment

  • Diagnosis is clinical and exclusionary - must rule out infection, vasculitis, malignancy, factitial disease
  • Pathergy (20-30% of cases): avoid debridement and surgical intervention, as trauma worsens lesions
  • Response to immunosuppression is itself a minor diagnostic criterion - failure to respond should prompt re-evaluation of the diagnosis

Step 1: Treat the Underlying Disease

Associated ConditionImplication
IBD (Crohn's / UC)Anti-TNF therapy overlaps; managing IBD often improves PG
Hematologic malignancyChemotherapy for underlying disease may resolve bullous PG
RADMARDs (methotrexate, anti-TNFs) serve dual purpose
Peristomal PGStoma revision or relocation may help; topical tacrolimus reported effective

Step 2: Local / Topical Therapy

Appropriate for vegetative type, solitary lesions, or slowly progressive disease.
  • Wound care: compresses or whirlpool baths followed by hydrophilic occlusive dressings
  • Potent topical corticosteroids (e.g., clobetasol): applied directly to lesion borders
  • Intralesional corticosteroid injections: caution - pathergy risk at injection sites
  • Topical tacrolimus 0.1-0.3%: effective, especially peristomal PG; systemic absorption possible in large wounds
  • Topical dapsone: adjunct option
  • Topical timolol: isolated case reports of benefit (BMJ Case Rep, 2017)
  • Topical corticosteroid powder: systematic review (PMID: 39500711) supports use in peristomal PG

Step 3: Systemic Therapy

First-Line Agents

DrugDosingNotes
Prednisolone / Prednisone1-2 mg/kg/day orallyRapid onset; taper once controlled
Methylprednisolone pulseIV, 3-5 daysFor rapidly progressive or severe disease
Cyclosporine4-5 mg/kg/daySTOP-GAP RCT validated 4 mg/kg; response independent of underlying cause
Infliximab5 mg/kg IV at weeks 0, 2, 6, then every 6-8 weeksValidated in RCT; most utilized biologic in PG
The landmark STOP-GAP trial (BMJ, 2015) compared prednisolone vs. cyclosporine - both were equally effective as first-line agents, informing current practice.

Biologic Therapies (First- or Second-Line)

A 2024 systematic review of 108 patients (PMID: 39158753) found 88.9% complete resolution with biologic therapies:
  • Infliximab (anti-TNF): most used (64.8% of biologic-treated cases); average time to resolution ~161 days
  • Adalimumab (anti-TNF): 16.7% of cases; 40-80 mg every other week; also effective for IBD-associated PG
  • Etanercept: 11.1% of cases; used as alternative
  • Canakinumab (anti-IL-1β): promising in small studies for steroid-refractory PG (Br J Dermatol, 2015)
  • Ustekinumab (anti-IL-12/23): reported in refractory cases

Second-Line / Steroid-Sparing Agents

Used when tapering steroids is not possible, or as adjuncts:
  • Mycophenolate mofetil (MMF)
  • Azathioprine
  • Methotrexate
  • Dapsone / Sulfasalazine / Sulfapyridine: less potent; useful for mild disease or contraindications to stronger agents
  • Minocycline: adjunct
  • Thalidomide: reserved for refractory cases
  • IVIG / granulocyte apheresis: case series support; considered in refractory disease
  • Systemic tacrolimus: for severe, recalcitrant cases (G Ital Dermatol Venereol, 2017)
  • Alkylating agents (cyclophosphamide, chlorambucil): reserved for severe refractory disease

Step 4: Monitoring Response

  • Expected response: within 1-2 weeks - reduced pain, less exudate, decreased erythema/edema
  • Once inflammation is controlled, taper systemic immunosuppression
  • Do not continue high-dose immunosuppression just for wound closure once inflammation is under control - the remaining wound can be managed with optimal dressings
  • Ongoing wound care is essential even after achieving inflammatory control

Special Situations

Postoperative / Surgical PG

  • Occurs at surgical incision sites; often misdiagnosed as wound infection
  • History of sterile wound cultures and multiple failed debridements is a clue
  • Avoid debridement - treat with systemic immunosuppression

Peristomal PG

  • Topical tacrolimus is well supported (Lyon et al., J Dermatol)
  • Anti-TNF therapy (IFX/ADA) effective when IBD is active
  • Stoma relocation may be considered

Childhood PG

  • 40% have IBD, ~18% have leukemia
  • Treat underlying cause first
  • Head/neck and genital involvement possible

Bullous PG (associated with hematologic malignancy)

  • Often overlaps with bullous Sweet syndrome
  • Managing the underlying hematologic disorder is central

Summary Algorithm

PG confirmed (clinical + exclusion)
     |
     +--> Identify & treat underlying disease
     |
     +--> Severity assessment
            |
            +--> Mild / solitary / vegetative
            |         --> Topical steroids / tacrolimus / wound care
            |
            +--> Moderate / progressive
            |         --> Systemic prednisolone 1-2 mg/kg/day
            |              OR cyclosporine 4 mg/kg/day (STOP-GAP)
            |              + wound care
            |
            +--> Severe / rapidly progressive
                      --> IV methylprednisolone pulse
                           + Infliximab (5 mg/kg)
                           --> Taper steroids, maintain biologic
                           --> Add steroid-sparing agent if needed

Key Evidence (Recent)

Sources: Andrews' Diseases of the Skin (Elsevier), p. 172-173; Tintinalli's Emergency Medicine, p. 253; Rheumatology 2-Volume Set (Elsevier), p. 610; Sleisenger & Fordtran's GI Disease

infliximab availability in india

Searching the Web

infliximab brands available India 2024 2025 price biosimilars

Searching the Web

infliximab brand names India Remsima Infimab Revellex price per vial INR 2024

Searching the Web

infliximab India CDSCO approved brands Remsima Zessly Infimab availability hospitals 2025

Here is a comprehensive overview of infliximab availability in India:

Infliximab Availability in India

Regulatory Status

Infliximab is approved in India by the Central Drugs Standard Control Organisation (CDSCO). India follows its own "similar biologics" regulatory pathway (not identical to EMA/FDA biosimilar pathways), under which several products have been approved.

Available Brands in India

Brand NameTypeManufacturer / MarketerNotes
RemicadeOriginatorJanssen (J&J)Reference product; available but expensive
Infimab (BOW015)Similar biologicEpirus Biopharmaceuticals / Reliance Life Sciences (manufactured in Mumbai)First infliximab similar biologic approved in India (Sept 2014); marketed by Ranbaxy (now Sun Pharma)
Remsima (CT-P13)BiosimilarCelltrion (South Korea)Available via importers/distributors (e.g., GNH India); most widely studied biosimilar globally
Zessly (PF-06438179)BiosimilarSandoz / PfizerAvailable in Indian market through specialty distributors
Note: Infliximab leads the Indian biosimilar market with 14% revenue share in 2025, driven by autoimmune disease adoption (RA, IBD, psoriasis). India is also a major manufacturer - Reliance Life Sciences produces Infimab domestically.

Approximate Cost (100 mg vial)

ProductApproximate Price (INR/vial)
Remicade (originator)~₹16,000 - ₹17,500
Infimab (biosimilar)~₹12,000 - ₹14,500
Remsima (imported biosimilar)~₹12,000 - ₹17,000
Prices from trade listings; actual hospital procurement prices will differ and are typically negotiated lower. Prices are approximate and subject to change.
Context for PG dosing: Standard infliximab dosing is 5 mg/kg at weeks 0, 2, 6, then every 6-8 weeks. For a 60 kg patient, that is ~300 mg per dose = 3 vials per infusion, putting the cost at roughly ₹36,000 - ₹52,000 per infusion for the biosimilar.

Indications Approved in India

  • Rheumatoid arthritis
  • Ankylosing spondylitis
  • Crohn's disease
  • Ulcerative colitis
  • Psoriatic arthritis
  • Plaque psoriasis
  • Behcet's disease
PG is an off-label indication for infliximab in India (as it is globally), though it is well-supported by RCT evidence and widely used in clinical practice.

Practical Access Considerations

FactorDetail
SettingIV infusion only; requires hospital/clinic infusion facility
Cold chainMust be refrigerated (2-8°C); not available at general retail pharmacies
ProcurementThrough specialty distributors, hospital pharmacies, or online exporters (GNH India, etc.)
Patient supportRanbaxy/Sun Pharma launched RAISE (Rheumatoid Ailment Infimab Support Endeavor) for patient access assistance
Government schemesNot currently on PMJAY (Ayushman Bharat) essential medicines list for PG specifically; IBD patients may access through GI specialty programs
MonitoringRequires pre-infusion TB screening (Mantoux/IGRA), baseline LFTs, CBC; infusion centre with resuscitation capability

Key Takeaway

For PG management in India, Infimab (the domestically manufactured biosimilar by Reliance Life Sciences) is the most pragmatic choice - CDSCO-approved, made in India, and priced significantly below the originator. Remsima (Celltrion, CT-P13) is the globally most-studied biosimilar and is also obtainable. The originator Remicade is available but rarely chosen given the cost differential. All require hospital-based IV infusion and appropriate pre-treatment workup.
This is a shared conversation. Sign in to Orris to start your own chat.